Trading on NYSE American Expected to Commence
Under Ticker Symbol "MNK" on October 27,
2022
DUBLIN, Oct. 24,
2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty
pharmaceutical company, today announced that it has received
approval to list its ordinary shares on NYSE American. Trading of
the Company's ordinary shares on NYSE American is expected to occur
under the ticker symbol "MNK" beginning on October 27, 2022.
Siggi Olafsson, President and
Chief Executive Officer, said, "Our listing on NYSE American marks
an important step toward executing on our strategic priorities and
business objectives. We are confident that Mallinckrodt is well positioned to drive
sustainable growth and create long-term shareholder value while
advancing therapies for underserved patients with severe and
critical conditions."
Mallinckrodt's listing is subject to
meeting all NYSE American requirements at the time of listing.
Trading on the OTC Pink Current Market will cease concurrent with
the NYSE American listing.
About Mallinckrodt
Mallinckrodt is a global
business consisting of multiple wholly owned subsidiaries that
develop, manufacture, market and distribute specialty
pharmaceutical products and therapies. The Company's Specialty
Brands reportable segment's areas of focus include autoimmune and
rare diseases in specialty areas like neurology, rheumatology,
hepatology, nephrology, pulmonology, ophthalmology and oncology;
immunotherapy and neonatal respiratory critical care therapies;
analgesics; cultured skin substitutes and gastrointestinal
products. Its Specialty Generics reportable segment includes
specialty generic drugs and active pharmaceutical ingredients. To
learn more about Mallinckrodt,
visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution
of important company information, such as press releases, investor
presentations and other financial information. It also uses its
website to expedite public access to time-critical information
regarding the Company in advance of or in lieu of distributing a
press release or a filing with the U.S. Securities and Exchange
Commission (SEC) disclosing the same information. Therefore,
investors should look to the Investor Relations page of the website
for important and time-critical information. Visitors to the
website can also register to receive automatic e-mail and other
notifications alerting them when new information is made available
on the Investor Relations page of the website.
CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING
STATEMENTS
Statements in this release that are not strictly
historical, including statements regarding Mallinckrodt's listing on NYSE American, future
financial condition and operating results, legal, economic,
business, competitive and/or regulatory factors affecting
Mallinckrodt's businesses, and any
other statements regarding events or developments Mallinckrodt believes or anticipates will or may
occur in the future, may be "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
and involve a number of risks and uncertainties. There are a number
of important factors that could cause actual events to differ
materially from those suggested or indicated by such
forward-looking statements and you should not place undue reliance
on any such forward-looking statements. The "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" sections of Mallinckrodt's Annual Report on Form 10-K for the
fiscal year ended December 31, 2021
and Quarterly Reports on Form 10-Q for the quarterly periods ended
July 1, 2022 and April 1, 2022, and other filings with the SEC,
all of which are on file with the SEC and available on Mallinckrodt's website at http://www.sec.gov and
http://www.mallinckrodt.com, respectively, identify and describe in
more detail the risks and uncertainties to which Mallinckrodt's businesses are subject. The
forward-looking statements made herein speak only as of the date
hereof and Mallinckrodt does not assume
any obligation to update or revise any forward-looking statement,
whether as a result of new information, future events and
developments or otherwise, except as required by law.
CONTACTS
Investor Relations
Daniel Speciale
Global Corporate Controller and Chief Investor Relations
Officer
314-654-3638
daniel.speciale@mnk.com
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Media
Michael Freitag / Aaron Palash / Aura
Reinhard
Joele Frank, Wilkinson Brimmer
Katcher
212-355-4449
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of
a Mallinckrodt company. Other brands are trademarks of
a Mallinckrodt company or their respective
owners. ©2022 10/22.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-receives-approval-to-list-on-nyse-american-301656644.html
SOURCE Mallinckrodt plc